BUZZ-Allarity more than doubles on US FDA's 'fast track' tag for ovarian cancer therapy

Reuters
Aug 26
BUZZ-Allarity more than doubles on US FDA's 'fast track' tag for ovarian cancer therapy

Updates

** Shares of drug developer Allarity Therapeutics ALLR.O rise 132% to over 10-month high of $2.19

** Stock set for its biggest one-day pct gain on record, if gains hold

** Co says U.S. FDA granted fast track designation to its experimental ovarian cancer therapy, stenoparib

** Stenoparib, an oral drug, works by blocking two enzymes that cancer cells use to repair themselves and keep growing

** FDA's "fast track" tag aims to speed development and review of drugs for serious conditions with unmet medical need

** The therapy was originally developed by Japan's Eisai 4523.T and later licensed to Allarity, which secured global rights to develop and commercialize the drug

** As of last close, stock down 20% YTD

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10